Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation

Transplant International

Volumn 21, Issue 6, 2008, Pages 523-530

  Roland, Mélanie ^a   Gatault, Philippe ^a   Doute, Claire ^a   Büchler, Matthias ^a   Al Najjar, Azmi ^a   Barbet, Christelle ^a   Chatelet, Valérie ^a   Marlière, Jean Frédéric ^a   Nivet, Hubert ^a   Lebranchu, Yvon ^a   Halimi, Jean Michel ^a  

^a CHU BRETONNEAU   (France)

Author keywords

Cyclosporine; Diabetes; Sirolimus; Steroid; Tacrolimus; Transplantation; Triglycerides

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; GLUCOSE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; PRIORITY JOURNAL; RISK FACTOR;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CYCLOSPORINE; DIABETES MELLITUS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SIROLIMUS; TACROLIMUS; TRIGLYCERIDES;

EID: 42649104756     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00640.x     Document Type: Article

References (38)

1. Montori VM., Velosa JA, Basu A, Gabriel SE, Erwin PJ, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002 25 : 583.
2. Markell M. Clinical impact of posttransplant diabetes mellitus. Transplant Proc 2001 33 (5A Suppl. 19S.
3. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after tansplantation: 2003 International Consensus Guidelines. Transplantation 2003 75 : SS3.
4. Arner O, Gunnarsson R, Blomdhal S, Groth CG. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high dose corticosteroid therapy. Diabetes Care 1983 6 : 23.
5. Friedman EA, Shyh TP, Beyer MM, et al. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985 5 : 196.
6. Baid-Agrawal S, Delmonico FL, Tolkoff-Rubin NE, et al. Cardiovascular risk profile after conversion from cyclosporine to tacrolimus in stable renal transplant recipients. Transplantation 2004 77 : 1199.
7. Hoitsma AJ, Hilbrands LB. Relative risk of new-onset diabetes during the first year after renal transplantation in patients receiving tacrolimus or cyclosporine immunosuppression. Clin Transplant 2006 20 : 659.
8. Shapiro Am, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immnosuppressive regimen. N Engl J Med 2000 343 : 230.
9. Zhang N, Su D, Qu S, et al. Sirolimus associated with reduced islet engraftment and impaired β-cell function. Diabetes 2006 55 : 2429.
10. Morrisett JD, Abdel-Fattah G, Hoogeven R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels and fatty acid metabolism in renal transplant recipients. J Lipid Res 2002 43 : 1170.
11. Romagnoli J, Citterio F, Nanni G, et al. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc 2006 38 : 1034.
12. Teutonico A, Schena PF, Di Paolo S. Glucose Metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005 16 : 3128.
13. Kreis H, Cistern JM, Land W, et al. Sirolimus in association with MMF induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000 69 : 1252.
14. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001 72 : 777.
15. Halimi JM, Laouad I, Büchler M, et al. Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant 2005 5 : 2281.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31.
17. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004 27 (Suppl. 1 S5.
18. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001 59 : 732.
19. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003 3 : 178.
20. Egidi F. Management of hyperglycaemia after pancreas transplantation: are new immunosuppressants the answer? Drugs 2005 65 : 153.
21. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004 22 : 909.
22. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007 356 : 2271.
23. Sulanc E, Lane JT, Puumala SE, et al. New onset diabetes after transplantation: an application of 2003 International Guidelines. Transplantation 2005 80 : 945.
24. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The rapamune US study group. Lancet 2000 356 : 194.
25. Araki M, Flechner SM, Ismail HR, et al. Posttransplantation Diabetes Mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 2006 82 : 335.
26. Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression and prognosis. Transplantation 2003 76 : 375.
27. Mathis AS, Dave N, Knipp GT, Friedman GS. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 2004 61 : 565.
28. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance. Endocr Rev 2002 23 : 210.
29. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004 27 (Suppl. 1 S11.
30. Sehgal SN. Rapamune: Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998 31 : 335.
31. Tremblay F, Gagnon AM, Veilleux A, et al. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signalling to akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology 2005 14 : 1328.
32. Krebs M, Brunmair B, Brehm A, et al. The mammalian target of rapamycine pathway regulates nutrient-sensitive glucose uptake in man. Diabetes 2007 56 : 1600.
33. Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF. Chronic inhibition of mammalian target of rapamycin signalling down regulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes. J Am Soc Nephrol 2006 17 : 2236.
34. Porrini E, Delgado P, Alvarez A, et al. The combined effect of pre-transplant triglycerides levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Nephrol Dial Transplant 2007 DOI:. [Epub ahead of print].
35. Park JB, Kim SJ, Oh HY, et al. Steroid withdrawal in living donor renal transplant recipients using tacrolimus and cyclosporine: a randomized prospective study. Transplant Int 2006 19 : 478.
36. Cheung CY, Wong KM, Chan HW, et al. Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients. Transplant Int 2006 19 : 657.
37. Kamar N, Mariat C, Delahousse M, et al. Diabetes mellitus after kidney transplantation: a French multicentre observational study. Nephrol Dial Transplant 2007 22 : 1986.
38. Ghisdal L, Bouchta NB, Broeders N, et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transplant Int 2008 21 : 146.